CD73–adenosine: a next-generation target in immuno-oncology

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Carta S, Penco F, Lavieri R et al. Cell stress increases ATP release in NLRP3 inflammasome-mediated autoinflammatory diseases, resulting in cytokine imbalance. Proc. Natl Acad. Sci. USA 112(9), 2835–2840 (2015).
  Medline CASGoogle Scholar
• 2 Elliott MR, Chekeni FB, Trampont PC et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461(7261), 282–286 (2009).
  Medline CASGoogle Scholar
• 3 Amoroso F, Falzoni S, Adinolfi E, Ferrari D, Di Virgilio F. The P2X7 receptor is a key modulator of aerobic glycolysis. Cell Death Dis. 3, e370 (2012).
  Medline CASGoogle Scholar
• 4 Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat. Rev. Cancer 13(12), 842–857 (2013).
  Medline CASGoogle Scholar
• 5 Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 19(6), 355–367 (2013).
  Medline CASGoogle Scholar
• 6 Allard B, Turcotte M, Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin. Ther. Targets 18(8), 863–881 (2014).
  Medline CASGoogle Scholar
• 7 Maksimow M, Kyhala L, Nieminen A et al. Early prediction of persistent organ failure by soluble CD73 in patients with acute pancreatitis*. Crit. Care Med. 42(12), 2556–2564 (2014).
  Medline CASGoogle Scholar
• 8 Niemela J, Ifergan I, Yegutkin GG, Jalkanen S, Prat A, Airas L. IFN-beta regulates CD73 and adenosine expression at the blood–brain barrier. Eur. J. Immunol. 38(10), 2718–2726 (2008).
  Medline CASGoogle Scholar
• 9 Chuang NN, Newby AC, Luzio JP. Characterization of different molecular forms of 5′-nucleotidase in normal serum and in serum from cholestatic patients and bile-duct-ligated rats. Biochem. J. 224(3), 689–695 (1984).
  Medline CASGoogle Scholar
• 10 Martin-Satue M, Lavoie EG, Fausther M et al. High expression and activity of ecto-5′-nucleotidase/CD73 in the male murine reproductive tract. Histochem. Cell Biol. 133(6), 659–668 (2010).
  Medline CASGoogle Scholar
• 11 Fini C, Talamo F, Cherri S et al. Biochemical and mass spectrometric characterization of soluble ecto-5′-nucleotidase from bull seminal plasma. Biochem. J. 372(Pt 2), 443–451 (2003).
  Medline CASGoogle Scholar
• 12 Johnson SM, Patel S, Bruckner FE, Collins DA. 5′-nucleotidase as a marker of both general and local inflammation in rheumatoid arthritis patients. Rheumatology (Oxford) 38(5), 391–396 (1999).
  Medline CASGoogle Scholar
• 13 Huang JL, Urtatiz O, Van Raamsdonk CD. Oncogenic G protein GNAQ induces uveal melanoma and intravasation in mice. Cancer Res. 75(16), 3384–3397 (2015).
  Medline CASGoogle Scholar
• 14 Blume C, Felix A, Shushakova N et al. Autoimmunity in CD73/Ecto-5′-nucleotidase deficient mice induces renal injury. PLoS ONE 7(5), e37100 (2012).
  Medline CASGoogle Scholar
• 15 Castrop H, Huang Y, Hashimoto S et al. Impairment of tubuloglomerular feedback regulation of GFR in ecto-5′-nucleotidase/CD73-deficient mice. J. Clin. Invest. 114(5), 634–642 (2004).
  Medline CASGoogle Scholar
• 16 Koszalka P, Ozuyaman B, Huo Y et al. Targeted disruption of cd73/ecto-5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 95(8), 814–821 (2004).
  Medline CASGoogle Scholar
• 17 Lennon PF, Taylor CT, Stahl GL, Colgan SP. Neutrophil-derived 5′-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A2B receptor activation. J. Exp. Med. 188(8), 1433–1443 (1998).
  Medline CASGoogle Scholar
• 18 Thompson LF, Eltzschig HK, Ibla JC et al. Crucial role for ecto-5′-nucleotidase (CD73) in vascular leakage during hypoxia. J. Exp. Med. 200(11), 1395–1405 (2004).
  Medline CASGoogle Scholar
• 19 Synnestvedt K, Furuta GT, Comerford KM et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110(7), 993–1002 (2002).
  Medline CASGoogle Scholar
• 20 Algars A, Karikoski M, Yegutkin GG et al. Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 117(16), 4387–4393 (2011).
  Medline CASGoogle Scholar
• 21 Mills JH, Thompson LF, Mueller C et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl Acad. Sci. USA 105(27), 9325–9330 (2008).
  Medline CASGoogle Scholar
• 22 Grenz A, Zhang H, Eckle T et al. Protective role of ecto-5′-nucleotidase (CD73) in renal ischemia. J. Am. Soc. Nephrol. 18(3), 833–845 (2007).
  Medline CASGoogle Scholar
• 23 Eckle T, Krahn T, Grenz A et al. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 115(12), 1581–1590 (2007).
  Medline CASGoogle Scholar
• 24 Peng Z, Fernandez P, Wilder T et al. Ecto-5′-nucleotidase (CD73) -mediated extracellular adenosine production plays a critical role in hepatic fibrosis. FASEB J. 22(7), 2263–2272 (2008).
  Medline CASGoogle Scholar
• 25 Muller G, Jung C, Wied S, Biemer-Daub G, Frick W. Transfer of the glycosylphosphatidylinositol-anchored 5′-nucleotidase CD73 from adiposomes into rat adipocytes stimulates lipid synthesis. Br. J. Pharmacol. 160(4), 878–891 (2010).
  Medline CASGoogle Scholar
• 26 Hasko G, Pacher P, Vizi ES, Illes P. Adenosine receptor signaling in the brain immune system. Trends Pharmacol. Sci. 26(10), 511–516 (2005).
  Medline CASGoogle Scholar
• 27 Deaglio S, Dwyer KM, Gao W et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204(6), 1257–1265 (2007). •• First report showing that adenosine produced by the sequential action of CD39 and CD73 is major immunosuppressive mechanism used by Tregs.
  Medline CASGoogle Scholar
• 28 Stagg J, Divisekera U, Duret H et al. CD73-deficient mice have increased anti-tumor immunity and are resistant to experimental metastasis. Cancer Res. 71(8), 2892–2900 (2011). •• First report showing that host CD73 is involved in anti-tumor immunity.
  Medline CASGoogle Scholar
• 29 St Hilaire C, Ziegler SG, Markello TC et al. NT5E mutations and arterial calcifications. N. Engl. J. Med. 364(5), 432–442 (2011).
  Medline CASGoogle Scholar
• 30 Fausther M, Lavoie EG, Goree JR, Baldini G, Dranoff JA. NT5E mutations that cause human disease are associated with intracellular mistrafficking of NT5E protein. PLoS ONE 9(6), e98568 (2014).
  MedlineGoogle Scholar
• 31 Li Q, Price TP, Sundberg JP, Uitto J. Juxta-articular joint-capsule mineralization in CD73 deficient mice: similarities to patients with NT5E mutations. Cell cycle (Georgetown, TX) 13(16), 2609–2615 (2014).
  Medline CASGoogle Scholar
• 32 Hoskin DW, Reynolds T, Blay J. 2-Chloroadenosine inhibits the MHC-unrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non-A1/A2 cell-surface adenosine receptor. Cell. Immunol. 159(1), 85–93 (1994).
  Medline CASGoogle Scholar
• 33 Hoskin DW, Reynolds T, Blay J. Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. Int. J. Cancer 59(6), 854–855 (1994).
  Medline CASGoogle Scholar
• 34 Mackenzie WM, Hoskin DW, Blay J. Adenosine inhibits the adhesion of anti-CD3-activated killer lymphocytes to adenocarcinoma cells through an A3 receptor. Cancer Res. 54(13), 3521–3526 (1994).
  Medline CASGoogle Scholar
• 35 Williams BA, Manzer A, Blay J, Hoskin DW. Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells. Biochem. Biophys. Res. Commun. 231(2), 264–269 (1997).
  Medline CASGoogle Scholar
• 36 Blay J, White TD, Hoskin DW. The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res. 57(13), 2602–2605 (1997). • First report showing that adenosine levels are elevated in the tumor microenvironment and capable of mediating immunosuppression.
  Medline CASGoogle Scholar
• 37 Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 90(4), 1600–1610 (1997).
  Medline CASGoogle Scholar
• 38 Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414(6866), 916–920 (2001). •• First report showing the importance of A2A activation for the protection of tissues against against inflammatory reactions.
  Medline CASGoogle Scholar
• 39 Ohta A, Gorelik E, Prasad SJ et al. A2A adenosine receptor protects tumors from anti-tumor T cells. Proc. Natl Acad. Sci. USA 103(35), 13132–13137 (2006). •• First report showing that a deficiency in host A2A receptors confers resitance to tumor growth in mice.
  Medline CASGoogle Scholar
• 40 Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res. 70(16), 6407–6411 (2010).
  Medline CASGoogle Scholar
• 41 Wang L, Fan J, Thompson LF et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121(6), 2371–2382 (2011).
  Medline CASGoogle Scholar
• 42 Stagg J, Divisekera U, Mclaughlin N et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107(4), 1547–1552 (2010). •• First report demonstrating that the targeted blockade of CD73 can reduce tumor growth and metastasis through the activation of anti-tumor immunity.
  Medline CASGoogle Scholar
• 43 Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the anti-tumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19(20), 5626–5635 (2013).
  Medline CASGoogle Scholar
• 44 Beavis PA, Divisekera U, Paget C et al. Blockade of A2A receptors potently suppresses the metastasis of CD73⁺ tumors. Proc. Natl Acad. Sci. USA 110(36), 14711–14716 (2013).
  Medline CASGoogle Scholar
• 45 Mittal D, Young A, Stannard K et al. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74(14), 3652–3658 (2014).
  Medline CASGoogle Scholar
• 46 Poth JM, Brodsky K, Ehrentraut H, Grenz A, Eltzschig HK. Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease. J. Mol. Med. (Berl.) 91(2), 183–193 (2013).
  Medline CASGoogle Scholar
• 47 Sitkovsky MV, Hatfield S, Abbott R et al. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol. Res. 2(7), 598–605 (2014).
  Medline CASGoogle Scholar
• 48 Turcotte M, Spring K, Pommey S et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 75(21), 4494–4503 (2015). •• First report showing that CD73 expression correlates with poor prognosis in tha major subtype of ovarian cancer.
  Medline CASGoogle Scholar
• 49 Leclerc BG, Charlebois R, Chouinard G et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin. Cancer. Res. doi:10.1158/1078-0432.CCR-15-1181 (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 50 Loi S, Pommey S, Haibe-Kains B et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl Acad. Sci. USA 110(27), 11091–11096 (2013). •• First clinical evidence that CD73 correlates with prognosis and response to therapy in triple-negative breast cancers.
  Medline CASGoogle Scholar
• 51 Sim GC, Martin-Orozco N, Jin L et al. IL-2 therapy promotes suppressive ICOS⁺ Treg expansion in melanoma patients. J. Clin. Invest. 124(1), 99–110 (2014).
  Medline CASGoogle Scholar
• 52 Chatterjee S, Thyagarajan K, Kesarwani P et al. Reducing CD73 expression by IL1beta-programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 74(21), 6048–6059 (2014).
  Medline CASGoogle Scholar
• 53 Mandapathil M, Szczepanski MJ, Szajnik M et al. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem. 285(36), 27571–27580 (2010).
  Medline CASGoogle Scholar
• 54 Bellingan G, Maksimow M, Howell DC et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir. Med. 2(2), 98–107 (2014).
  Medline CASGoogle Scholar
• 55 Sadej R, Skladanowski AC. Dual, enzymatic and non-enzymatic, function of ecto-5′-nucleotidase (eN, CD73) in migration and invasion of A375 melanoma cells. Acta Biochim. Pol. 59(4), 647–652 (2012).
  Medline CASGoogle Scholar
• 56 Allard B, Turcotte M, Spring K et al. Anti-CD73 therapy impairs tumor angiogenesis. Int. J. Cancer 134(6), 1466–1473 (2014).
  Medline CASGoogle Scholar
• 57 Long JS, Schoonen PM, Graczyk D, O'prey J, Ryan KM. p73 engages A2B receptor signalling to prime cancer cells to chemotherapy-induced death. Oncogene 34(40), 5152–5162 (2015).
  Medline CASGoogle Scholar
• 58 El-Darahali A, Fawcett H, Mader JS, Conrad DM, Hoskin DW. Adenosine-induced apoptosis in EL-4 thymoma cells is caspase-independent and mediated through a non-classical adenosine receptor. Exp. Mol. Pathol. 79(3), 249–258 (2005).
  Medline CASGoogle Scholar
• 59 Freundlieb M, Zimmermann H, Muller CE. A new, sensitive ecto-5′-nucleotidase assay for compound screening. Anal. Biochem. 446, 53–58 (2014).
  Medline CASGoogle Scholar
• 60 Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 115(2), 423–428 (2009).
  MedlineGoogle Scholar
• 61 Cancello G, Maisonneuve P, Rotmensz N et al. Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann. Oncol. 21(10), 1974–1981 (2010).
  Medline CASGoogle Scholar
• 62 Wang L, Zhou X, Zhou T et al. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J. Cancer Res. Clin. Oncol. 134(3), 365–372 (2008).
  Medline CASGoogle Scholar
• 63 Mediavilla-Varela M, Luddy K, Noyes D et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol. Ther. 14(9), 860–868 (2013).
  Medline CASGoogle Scholar
• 64 Cekic C, Sag D, Day YJ, Linden J. Extracellular adenosine regulates naive T cell development and peripheral maintenance. J. Exp. Med. 210(12), 2693–2706 (2013).
  Medline CASGoogle Scholar
• 65 Ripphausen P, Freundlieb M, Brunschweiger A, Zimmermann H, Muller CE, Bajorath J. Virtual screening identifies novel sulfonamide inhibitors of ecto-5′-nucleotidase. J. Med. Chem. 55(14), 6576–6581 (2012).
  Medline CASGoogle Scholar
• 66 Oh HK, Sin JI, Choi J, Park SH, Lee TS, Choi YS. Overexpression of CD73 in epithelial ovarian carcinoma is associated with better prognosis, lower stage, better differentiation and lower regulatory T cell infiltration. J. Gynecol. Oncol. 23(4), 274–281 (2012).
  Medline CASGoogle Scholar
• 67 Bhattarai S, Freundlieb M, Pippel J et al. Alpha, beta-methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5′-nucleotidase (CD73) inhibitors. J. Med. Chem. 58(15), 6248–6263 (2015).
  Medline CASGoogle Scholar
• 68 Baqi Y, Lee SY, Iqbal J et al. Development of potent and selective inhibitors of ecto-5′-nucleotidase based on an anthraquinone scaffold. J. Med. Chem. 53(5), 2076–2086 (2010).
  Medline CASGoogle Scholar
• 69 Iqbal J, Saeed A, Raza R et al. Identification of sulfonic acids as efficient ecto-5′-nucleotidase inhibitors. Eur. J. Med. Chem. 70, 685–691 (2013).
  Medline CASGoogle Scholar
• 70 Braganhol E, Tamajusuku AS, Bernardi A, Wink MR, Battastini AM. Ecto-5′-nucleotidase/CD73 inhibition by quercetin in the human U138MG glioma cell line. Biochim. Biophys. Acta 1770(9), 1352–1359 (2007).
  Medline CASGoogle Scholar
• 71 Thomson LF, Ruedi JM, Glass A et al. Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5′-nucleotidase (CD73). Tissue Antigens 35(1), 9–19 (1990).
  Medline CASGoogle Scholar
• 72 Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Ther. Adv. Med. Oncol. 5(3), 169–181 (2013).
  Medline CASGoogle Scholar
• 73 Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer. Res. 13(15 Pt 1), 4429–4434 (2007).
  MedlineGoogle Scholar
• 74 Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9), 1721–1728 (2007).
  MedlineGoogle Scholar
• 75 Anders CK, Deal AM, Miller CR et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117(8), 1602–1611 (2011).
  MedlineGoogle Scholar
• 76 Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747–752 (2000).
  Medline CASGoogle Scholar
• 77 Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10(16), 5367–5374 (2004).
  Medline CASGoogle Scholar
• 78 Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21), 2492–2502 (2006).
  Medline CASGoogle Scholar
• 79 Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26(8), 1275–1281 (2008).
  MedlineGoogle Scholar
• 80 O'Toole SA, Beith JM, Millar EK et al. Therapeutic targets in triple negative breast cancer. J. Clin. Pathol. 66(6), 530–542 (2013).
  MedlineGoogle Scholar
• 81 Rust S, Guillard S, Sachsenmeier K et al. Combining phenotypic and proteomic approaches to identify membrane targets in a ‘triple negative’ breast cancer cell type. Mol. Cancer 12, 11 (2013).
  Medline CASGoogle Scholar
• 82 Terp MG, Olesen KA, Arnspang EC et al. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J. Immunol. 191(8), 4165–4173 (2013).
  Medline CASGoogle Scholar
• 83 Spychala J, Lazarowski E, Ostapkowicz A, Ayscue LH, Jin A, Mitchell BS. Role of estrogen receptor in the regulation of ecto-5′-nucleotidase and adenosine in breast cancer. Clin. Cancer Res. 10(2), 708–717 (2004).
  Medline CASGoogle Scholar
• 84 Zhi X, Chen S, Zhou P et al. RNA interference of ecto-5′-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin. Exp. Metastasis 24(6), 439–448 (2007).
  Medline CASGoogle Scholar
• 85 Zhi X, Wang Y, Zhou X et al. RNAi-mediated CD73 suppression induces apoptosis and cell-cycle arrest in human breast cancer cells. Cancer Sci. 101(12), 2561–2569 (2010).
  Medline CASGoogle Scholar
• 86 Zhou X, Zhi X, Zhou P et al. Effects of ecto-5′-nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncol. Rep. 17(6), 1341–1346 (2007).
  Medline CASGoogle Scholar
• 87 Zhou JZ, Riquelme MA, Gao X et al. Differential impact of adenosine nucleotides released by osteocytes on breast cancer growth and bone metastasis. Oncogene 34(14), 1831–1842 (2015).
  Medline CASGoogle Scholar
• 88 Virtanen SS, Kukkonen-Macchi A, Vainio M et al. Adenosine inhibits tumor cell invasion via receptor-independent mechanisms. Mol. Cancer Res. 12(12), 1863–1874 (2014).
  Medline CASGoogle Scholar
• 89 Wang L, Tang S, Wang Y et al. Ecto-5′-nucleotidase (CD73) promotes tumor angiogenesis. Clin. Exp. Metastasis 30(5), 671–680 (2013).
  Medline CASGoogle Scholar
• 90 Desmet CJ, Gallenne T, Prieur A et al. Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc. Natl. Acad. Sci. USA 110(13), 5139–5144 (2013).
  Medline CASGoogle Scholar
• 91 Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J. Immunol. 188(1), 198–205 (2012).
  Medline CASGoogle Scholar
• 92 Ntantie E, Gonyo P, Lorimer EL et al. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci. Signal. 6(277), ra39 (2013).
  MedlineGoogle Scholar
• 93 Coustan-Smith E, Song G, Clark C et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood 117(23), 6267–6276 (2011).
  Medline CASGoogle Scholar
• 94 Serra S, Horenstein AL, Vaisitti T et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118(23), 6141–6152 (2011).
  Medline CASGoogle Scholar
• 95 Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk. Lymphoma 54(11), 2351–2364 (2013).
  Medline CASGoogle Scholar
• 96 Lad DP, Varma S, Varma N et al. Regulatory T-cells in B-cell chronic lymphocytic leukemia: their role in disease progression and autoimmune cytopenias. Leuk. Lymphoma 54(5), 1012–1019 (2013).
  Medline CASGoogle Scholar
• 97 Abousamra NK, Salah El-Din M, Hamza Elzahaf E, Esmael ME. Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia. Leuk. Lymphoma 56(1), 113–119 (2015).
  Medline CASGoogle Scholar
• 98 Bavaresco L, Bernardi A, Braganhol E et al. The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation. Mol. Cell. Biochem. 319(1–2), 61–68 (2008).
  Medline CASGoogle Scholar
• 99 Xu S, Shao QQ, Sun JT et al. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol. 15(9), 1160–1172 (2013).
  Medline CASGoogle Scholar
• 100 Quezada C, Garrido W, Oyarzun C et al. 5′-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells. J. Cell. Physiol. 228(3), 602–608 (2013).
  Medline CASGoogle Scholar
• 101 Tso CL, Shintaku P, Chen J et al. Primary glioblastomas express mesenchymal stem-like properties. Mol. Cancer Res. 4(9), 607–619 (2006).
  Medline CASGoogle Scholar
• 102 Liu TZ, Wang X, Bai YF et al. The HIF-2alpha dependent induction of PAP and adenosine synthesis regulates glioblastoma stem cell function through the A2B adenosine receptor. Int. J. Biochem. Cell Biol. 49, 8–16 (2014).
  MedlineGoogle Scholar
• 103 Daniele S, Zappelli E, Natali L, Martini C, Trincavelli ML. Modulation of A1 and A2B adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell Death Dis. 5, e1539 (2014).
  Medline CASGoogle Scholar
• 104 Synowitz M, Glass R, Farber K et al. A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res. 66(17), 8550–8557 (2006).
  Medline CASGoogle Scholar
• 105 Bynoe MS, Viret C, Yan A, Kim DG. Adenosine receptor signaling: a key to opening the blood–brain door. Fluids Barriers CNS 12(1), 20 (2015).
  MedlineGoogle Scholar
• 106 Carman AJ, Mills JH, Krenz A, Kim DG, Bynoe MS. Adenosine receptor signaling modulates permeability of the blood–brain barrier. J. Neurosci. 31(37), 13272–13280 (2011).
  Medline CASGoogle Scholar
• 107 Chen GQ, Chen YY, Wang XS et al. Chronic caffeine treatment attenuates experimental autoimmune encephalomyelitis induced by guinea pig spinal cord homogenates in Wistar rats. Brain Res. 1309, 116–125 (2010).
  Medline CASGoogle Scholar
• 108 Tsutsui S, Schnermann J, Noorbakhsh F et al. A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J. Neurosci. 24(6), 1521–1529 (2004).
  Medline CASGoogle Scholar
• 109 Mills JH, Alabanza LM, Mahamed DA, Bynoe MS. Extracellular adenosine signaling induces CX3CL1 expression in the brain to promote experimental autoimmune encephalomyelitis. J. Neuroinflammation 9, 193 (2012).
  Medline CASGoogle Scholar
• 110 Shechter R, Miller O, Yovel G et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 38(3), 555–569 (2013).
  Medline CASGoogle Scholar
• 111 Mills JH, Alabanza L, Weksler BB et al. Human brain endothelial cells are responsive to adenosine receptor activation. Purinergic Signal. 7(2), 265–273 (2011).
  Medline CASGoogle Scholar
• 112 Kim DG, Bynoe MS. A2A adenosine receptor regulates the human blood–brain barrier permeability. Mol. Neurobiol. 52(1), 664–678 (2015).
  Medline CASGoogle Scholar
• 113 Petrovic-Djergovic D, Hyman MC, Ray JJ et al. Tissue-resident ecto-5′ nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain. J. Immunol. 188(5), 2387–2398 (2012).
  Medline CASGoogle Scholar
• 114 Yao SQ, Li ZZ, Huang QY et al. Genetic inactivation of the adenosine A(2A) receptor exacerbates brain damage in mice with experimental autoimmune encephalomyelitis. J. Neurochem. 123(1), 100–112 (2012).
  Medline CASGoogle Scholar
• 115 Stagg J, Loi S, Divisekera U et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108(17), 7142–7147 (2011).
  Medline CASGoogle Scholar
• 116 Stagg J, Beavis PA, Divisekera U et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 72(9), 2190–2196 (2012).
  Medline CASGoogle Scholar
• 117 Cekic C, Day YJ, Sag D, Linden J. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 74(24), 7250–7259 (2014).
  Medline CASGoogle Scholar
• 118 Hatfield SM, Kjaergaard J, Lukashev D et al. Immunological mechanisms of the anti-tumor effects of supplemental oxygenation. Sci. Transl. Med. 7(277), 277ra230 (2015).
  Google Scholar
• 119 Ryzhov S, Novitskiy SV, Zaynagetdinov R et al. Host A(2B) adenosine receptors promote carcinoma growth. Neoplasia 10(9), 987–995 (2008).
  Medline CASGoogle Scholar
• 120 Sunaga N, Shames DS, Girard L et al. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy. Mol. Cancer Ther. 10(2), 336–346 (2011).
  Medline CASGoogle Scholar
• 121 Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66(8), 3992–3995 (2006).
  Medline CASGoogle Scholar
• 122 Algars A, Lintunen M, Carpen O, Ristamaki R, Sundstrom J. EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer. Br. J. Cancer 105(2), 255–262 (2011).
  Medline CASGoogle Scholar
• 123 Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25(22), 3230–3237 (2007).
  Medline CASGoogle Scholar
• 124 Rao S, Yang H, Penninger JM, Kroemer G. Autophagy in non-small cell lung carcinogenesis: a positive regulator of anti-tumor immunosurveillance. Autophagy 10(3), 529–531 (2014).
  Medline CASGoogle Scholar
• 125 Sadej R, Spychala J, Skladanowski AC. Expression of ecto-5′-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Res. 16(3), 213–222 (2006).
  Medline CASGoogle Scholar
• 126 Sadej R, Spychala J, Skladanowski AC. Ecto-5′-nucleotidase (eN, CD73) is coexpressed with metastasis promoting antigens in human melanoma cells. Nucleosides Nucleotides Nucleic Acids 25(9–11), 1119–1123 (2006).
  Medline CASGoogle Scholar
• 127 Wang H, Lee S, Nigro CL et al. NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. Br. J. Cancer 106(8), 1446–1452 (2012).
  Medline CASGoogle Scholar
• 128 Yegutkin GG, Marttila-Ichihara F, Karikoski M et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur. J. Immunol. 41(5), 1231–1241 (2011).
  Medline CASGoogle Scholar
• 129 Burghoff S, Gong X, Viethen C et al. Growth and metastasis of B16-F10 melanoma cells is not critically dependent on host CD73 expression in mice. BMC Cancer 14, 898 (2014).
  MedlineGoogle Scholar
• 130 Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 4(2), 172–181 (2014).
  MedlineGoogle Scholar
• 131 Koszalka P, Pryszlak A, Golunska M et al. Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro but results in impaired angiogenesis and reduced melanoma growth in vivo. Oncol. Rep. 31(2), 819–827 (2014).
  Medline CASGoogle Scholar
• 132 Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol. Immunother. 61(6), 917–926 (2012).
  Medline CASGoogle Scholar
• 133 Forte G, Sorrentino R, Montinaro A et al. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J. Immunol. 189(5), 2226–2233 (2012).
  Medline CASGoogle Scholar
• 134 Kaji W, Tanaka S, Tsukimoto M, Kojima S. Adenosine A(2B) receptor antagonist PSB603 suppresses tumor growth and metastasis by inhibiting induction of regulatory T cells. J. Toxicol. Sci. 39(2), 191–198 (2014).
  Medline CASGoogle Scholar
• 135 Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma. Neoplasia 15(12), 1400–1409 (2013).
  MedlineGoogle Scholar
• 136 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225–249 (2009).
  MedlineGoogle Scholar
• 137 Hamanishi J, Mandai M, Ikeda T et al. Safety and anti-tumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33(34), 4015–4022 (2015).
  Medline CASGoogle Scholar
• 138 Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73(12), 3591–3603 (2013).
  Medline CASGoogle Scholar
• 139 Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210(7), 1389–1402 (2013).
  Medline CASGoogle Scholar
• 140 Jin D, Fan J, Wang L et al. CD73 on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70(6), 2245–2255 (2010).
  Medline CASGoogle Scholar
• 141 Bignotti E, Tassi RA, Calza S et al. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am. J. Obstet. Gynecol. 196(3), 245.e241–245.e211 (2007).
  Google Scholar
• 142 Govindaraj C, Scalzo-Inguanti K, Madondo M et al. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2⁺ Tregs within the tumor microenvironment. Clin. Immunol. 149(1), 97–110 (2013).
  Medline CASGoogle Scholar
• 143 Hausler SF, Montalban Del Barrio I, Strohschein J et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol. Immunother. 60(10), 1405–1418 (2011).
  MedlineGoogle Scholar
• 144 Hausler SF, Del Barrio IM, Diessner J et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am. J. Transl. Res. 6(2), 129–139 (2014).
  MedlineGoogle Scholar
• 145 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374–1403 (2013).
  Medline CASGoogle Scholar
• 146 Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 358(12), 1250–1261 (2008).
  Medline CASGoogle Scholar
• 147 Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670–3679 (2009).
  Medline CASGoogle Scholar
• 148 Kantoff PW, Schuetz TJ, Blumenstein BA et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099–1105 (2010).
  Medline CASGoogle Scholar
• 149 Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089–3094 (2006).
  Medline CASGoogle Scholar
• 150 Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol. Oncol. Res. 19(4), 811–814 (2013).
  Medline CASGoogle Scholar
• 151 Mousavi S, Panjehpour M, Izadpanahi MH, Aghaei M. Expression of adenosine receptor subclasses in malignant and adjacent normal human prostate tissues. Prostate 75(7), 735–747 (2015).
  Medline CASGoogle Scholar
• 152 Peyot ML, Gadeau AP, Dandre F, Belloc I, Dupuch F, Desgranges C. Extracellular adenosine induces apoptosis of human arterial smooth muscle cells via A(2b)-purinoceptor. Circ. Res. 86(1), 76–85 (2000).
  Medline CASGoogle Scholar
• 153 Hajiahmadi S, Panjehpour M, Aghaei M, Shabani M. Activation of A2b adenosine receptor regulates ovarian cancer cell growth: involvement of Bax/Bcl-2 and caspase-3. Biochem. Cell Biol. 93(4), 321–329 (2015).
  Medline CASGoogle Scholar
• 154 Long JS, Crighton D, O'prey J et al. Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53. Mol. Cell 50(3), 394–406 (2013).
  Medline CASGoogle Scholar
• 155 Hay C, Sult E, Huang Q et al. MEDI9447: enhancing anti-tumor immunity by targeting CD73 in the tumor microenviroment. Presented at: 106th Annual Meeting of the American Association for Cancer Research. Philadelphia, PA, USA, 18–22 April 2015.
  Google Scholar
• 156 Zhi X, Wang Y, Yu J et al. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer. IUBMB Life 64(11), 911–920 (2012).
  Medline CASGoogle Scholar
• 157 Supernat A, Markiewicz A, Welnicka-Jaskiewicz M et al. CD73 expression as a potential marker of good prognosis in breast carcinoma. Appl. Immunohistochem. Mol. Morphol. 20(2), 103–107 (2012).
  Medline CASGoogle Scholar
• 158 Lo Nigro C, Monteverde M, Lee S et al. NT5E CpG island methylation is a favourable breast cancer biomarker. Br. J. Cancer 107(1), 75–83 (2012).
  Medline CASGoogle Scholar
• 159 Yang Q, Du J, Zu L. Overexpression of CD73 in prostate cancer is associated with lymph node metastasis. Pathol. Oncol. Res. 19(4), 811–814 (2013).
  Medline CASGoogle Scholar
• 160 Zhang B, Song B, Wang X et al. The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma. Tumour Biol. 36(7), 5459–5466 (2015).
  Medline CASGoogle Scholar
• 161 Wu XR, He XS, Chen YF et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J. Surg. Oncol. 106(2), 130–137 (2012).
  Medline CASGoogle Scholar
• 162 Xiong L, Wen Y, Miao X, Yang Z. NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer. Cell Tissue Res. 355(2), 365–374 (2014).
  Medline CASGoogle Scholar
• 163 Lu XX, Chen YT, Feng B, Mao XB, Yu B, Chu XY. Expression and clinical significance of CD73 and hypoxia-inducible factor-1alpha in gastric carcinoma. World J. Gastroenterol. 19(12), 1912–1918 (2013).
  Medline CASGoogle Scholar
• 164 Yu YI, Wang W, Song L et al. Ecto-5′-nucleotidase expression is associated with the progression of renal cell carcinoma. Oncol. Lett. 9(6), 2485–2494 (2015).
  Medline CASGoogle Scholar
• 165 Wettstein MS, Buser L, Hermanns T et al. CD73 predicts favorable prognosis in patients with nonmuscle-invasive urothelial bladder cancer. Disease Marker 2015(1), 1–8 (2015).
  Google Scholar